Header Logo

Connection

Cynthia Comella to Severity of Illness Index

Back to Details
This is a "connection" page, showing publications Cynthia Comella has written about Severity of Illness Index.
Cynthia Comella
Connection Strength
1.684
Severity of Illness Index
  1. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism Relat Disord. 2018 07; 52:94-97.
    View in: PubMed
    Score: 0.443
  2. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.386
  3. Reliability, feasibility and satisfaction of telemedicine evaluations for cervical dystonia. J Telemed Telecare. 2020 Oct; 26(9):560-567.
    View in: PubMed
    Score: 0.121
  4. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(?)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707.
    View in: PubMed
    Score: 0.080
  5. Dystonia rating scales: critique and recommendations. Mov Disord. 2013 Jun 15; 28(7):874-83.
    View in: PubMed
    Score: 0.080
  6. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug; 28(9):1230-40.
    View in: PubMed
    Score: 0.079
  7. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.076
  8. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.047
  9. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003 Mar; 18(3):303-312.
    View in: PubMed
    Score: 0.039
  10. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.028
  11. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord. 1997 Jul; 12(4):570-5.
    View in: PubMed
    Score: 0.026
  12. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63.
    View in: PubMed
    Score: 0.023
  13. IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
    View in: PubMed
    Score: 0.022
  14. Subthalamic nucleus--sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease. Neurobiol Aging. 2015 Jan; 36(1):462-9.
    View in: PubMed
    Score: 0.021
  15. Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015 Feb; 29(2):112-22.
    View in: PubMed
    Score: 0.021
  16. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar; 44(3 Pt 1):376-8.
    View in: PubMed
    Score: 0.021
  17. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013 Aug; 12(8):747-55.
    View in: PubMed
    Score: 0.020
  18. Pre-operative evaluations for DBS in dystonia. Mov Disord. 2011 Jun; 26 Suppl 1:S17-22.
    View in: PubMed
    Score: 0.017
  19. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.017
  20. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.017
  21. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease. Mov Disord. 2010 Oct 15; 25(13):2035-43.
    View in: PubMed
    Score: 0.017
  22. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord. 2010 Aug 15; 25(11):1627-32.
    View in: PubMed
    Score: 0.016
  23. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009 Apr 21; 72(16):1378-84.
    View in: PubMed
    Score: 0.015
  24. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008; 14(5):407-14.
    View in: PubMed
    Score: 0.014
  25. Control of movement distance in Parkinson's disease. Mov Disord. 2001 Nov; 16(6):1048-65.
    View in: PubMed
    Score: 0.009
  26. A teaching videotape for the assessment of essential tremor. Mov Disord. 2001 Jan; 16(1):89-93.
    View in: PubMed
    Score: 0.008
  27. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8.
    View in: PubMed
    Score: 0.008
  28. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46.
    View in: PubMed
    Score: 0.008
  29. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 1993 Jun; 16(3):205-10.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.